An announcement was made today by BioMarin Pharmaceutical Inc. that Doctor John Pasi will be presenting data in a late-breaking abstract session which will take place in Melbourne from 6th to 10th July. More than 5 thousand experts from nearly 90 countries in the field will gather to give a presentation on the most recent, clinical & translational research and discussion will be held on diagnostic, as well as, therapeutic advances in the clotting & bleeding disorders.

Managing Director, as well as, President of Worldwide R&D at BioMarin, Hank Fuchs stated that their firm was highly pleased to share the clinical data on our latest investigational gene therapy treatment for serious hemophilia in a late-breaking abstract session at the pioneering scientific event. Our research has the potential for addressing the vital unmet medical need, as well as, doing advancement in the standard of care.

ISTH was discovered in 1969. This firm is the pioneering worldwide non-profit firm dedicated to progressing the understanding, avoidance, diagnosis, and the treatment of bleeding & thrombotic disorders.  ISTH is a global professional membership firm with over 5,000 researchers, clinicians, and educators working together for the improvement of the lives of the patients in more than hundred countries all across the world. Amongst its highly recognized initiatives & activities are the standard programs, research activities, education, annual congresses, and expert committees.

People with the condition ‘hemophilia A’ do not have sufficient FVIII protein which is necessary for the clotting of blood, and hence are at risk for painful, potentially dangerous bleeds even from slightest injuries. In addition to this, people with severe hemophilia A frequently experience painful, sudden bleeds into their joints or muscles.